

Prof. Hartmann - Publikationen

- 1) Von Wussow P, Block B, Hartmann F, Deicher H (1988).
Intralesional interferon-alpha therapy in advanced malignant melanoma.
Cancer 61 (6): 1071-1074
- 2) Von Wussow P, Hartmann F, Freund M, Poliwoda H, Deicher H (1988).
Leucocyte-derived interferon-alpha in patients with antibodies to recombinant
interferon-alpha 2b (letter).
The Lancet I/1988 No. 8590: 882-883
- 3) Von Wussow P, Hartmann F, Jakschies D (1988).
Interferone - ein neues Behandlungsprinzip in der Onkologie ?
Fortschr. Med. 106 (34): 679-683
- 4) Hartmann F, von Wussow P, Deicher H (1989).
Psoriasis-Exazerbation bei Therapie mit α -Interferon.
Dtsch. Med. Wschr. 114 (3): 96-98
- 5) Sahin U, Hartmann F, Senter P, Pohl C, Engert A, Diehl V, Pfreundschuh M (1990).
Specific activation of the prodrug mitomycin phosphate by a bispecific anti-CD30
/anti-alkaline phosphatase antibody.
Cancer Research 50 (21): 6944-6948
- 6) Hartmann F, Gheorghiu T, Leupold H, Baer F, Diehl V (1991).
Serratia infections in patients with neutropenia.
Klin. Wochenschr. 69 (11): 491-494
- 7) Smyth MS, Stefanova I, Hartmann F, Horak ID, Osherov N, Levitzki A,
Burke Jr. TR (1993).
Non-amine based analogues of Lavendustin A as protein-tyrosine kinase inhibitors.
J. Med. Chem. 36 (20): 3010-3014
- 8) Hartmann F, Horak EM, Garmestani K, Wu C, Brechbiel MW, Kozak RW, Tso J,
Kostelny SA, Gansow OA, Nelson DL, Waldmann TA (1994).
Radioimmunotherapy of nude mice bearing a human Interleukin 2 Receptor α -
expressing lymphoma utilizing the α -emitting radionuclide-conjugated monoclonal
antibody ^{212}Bi -anti-Tac.
Cancer Research 54: 4362-4370
- 9) Renner C, Jung W, Sahin U, Denfeld R, Pohl C, Trümper L, Hartmann F,
Diehl V, van Lier R, Pfreundschuh M (1994).

Cure of xenografted human tumors by bispecific monoclonal antibodies and human T cells.
Science 264: 833-835

- 10) Hartmann F, Pfreunds Schuh M, Diehl V (1996).
Prognose und Therapie des Morbus Hodgkin.
Med. Klinik 91: 75-79 (Sondernr.3)
- 11) Hartmann F, Renner C, Pfreunds Schuh M (1996).
Tumor immunotherapy with bispecific antibodies.
Onkologie 19 (2): 114-117
- 12) Hartmann F, Bangerter M, Pfreunds Schuh M (1996).
Die Diagnostik des Hodgkin-Lymphoms.
Der Onkologe 2 (2): 132-137
- 13) Hartmann F, Renner C, Jung W, Sahin U, Pfreunds Schuh M (1996).
Treatment of Hodgkin's disease with bispecific antibodies.
Ann. Oncol. 7 (Suppl. 4): S143-S146
- 14) Trümper L, Hartmann F, Kranzhöfer N, Pfreunds Schuh M (1996).
Untersuchungen zur Stadieneinteilung beim Morbus Hodgkin.
Tumordiagn. u. Ther. 17 (5): 154-157
- 15) Hartmann F, Horak EM, Cho C, Lupu R, Bolen JB, Stetler-Stevenson MA,
Pfreunds Schuh M, Waldmann TA, Horak ID (1997).
Effects of the tyrosine kinase inhibitor geldanamycin on ligand induced Her-2/neu
activation, receptor expression, and proliferation of Her-2 positive malignant cell
lines.
Int. J. Cancer 70 (2): 221-229
- 16) Hartmann F, Pfreunds Schuh M (1997).
Update Onkologie '96
Med. Klinik 92 (2): 83-100
- 17) Hartmann F, Renner C, Jung W, Deisting C, Juwana M, Eichentopf B, Kloft M,
Pfreunds Schuh M (1997).
Treatment of refractory Hodgkin's disease with a natural killer cell activating
bispecific antibody.
Blood 89 (6): 2042-2047
- 18) Hartmann F, Renner C, Pfreunds Schuh M (1997).

Nutzung monoklonaler Antikörper für neue Strategien in der Tumorthherapie.
Arzneimitteltherapie 15 (10): 312-318

- 19) Schlenk RF, Döhner H, Pförsich M, Benner A, Fischer K, Hartmann F, Fischer JT, Weber W, Gunzer U, Pralle H, Haas R (1997).
Successful collection of peripheral blood progenitor cells in patients with acute myeloid leukemia following early consolidation therapy with granulocyte colony-stimulating factor-supported high-dose cytarabine and mitoxantrone.
Br. J. Haematol. 99 (2): 386-393
- 20) Renner C, Hartmann F, Pfreundschuh M (1997).
Treatment of refractory Hodgkin's disease with an anti- CD16/CD30 bispecific antibody.
Cancer Immunol. Immunother. 45 (3/4): 184-186
- 21) Horak E, Hartmann F, Garmestani K, Wu C, Brechbiel M, Gansow OA, Landolfi NF, Waldmann TA (1997).
Radioimmunotherapy targeting of HER2/neu oncoprotein on ovarian tumor using lead-212-DOTA-AE1.
J. Nucl. Med. 38 (12): 1944-1950
- 22) Zuber M, Kranzhöfer N, Lindemuth R, Hartmann F (1998).
Eine Patientin mit Mischkollagenose, Antiphospholipid-Syndrom und Sjögren-Syndrom.
Med. Klinik 93 (1): 34-38
- 23) Hartmann F, Renner C, Jung W, Deisting C, Juwana M, Eichentopf B, Kloft M, Pfreundschuh M (1998).
Treatment of refractory Hodgkin's disease with a natural killer cell activating bispecific antibody.
Biotherapy in Cancer 2 (1): 10-11
- 24) Mehl AM, Fischer N, Rowe M, Hartmann F, Daus H, Trümper L, Pfreundschuh M, Müller-Lantsch N, Grässer FA (1998).
Isolation and analysis of two strongly transforming isoforms of the Epstein-Barr-Virus(EBV)-encoded latent membrane protein-1 (LMP1) from a single Hodgkin's lymphoma.
Int. J. Cancer 76 (2): 194-200
- 25) Hartmann F, Renner C, Jung W, Pfreundschuh M (1998).
Anti- CD16/CD30 bispecific antibodies as possible treatment of refractory Hodgkin's disease.
Leuk. Lymphoma 31 (3/4): 385-392

- 26) Hartmann F (1999).
Das Kolonkarzinom - ein Tumor mit Modellcharakter ?
Saarländisches Ärzteblatt 10/99: 26-32
- 27) Renner C, Hartmann F, Jung W, Deisting C, Juwana M, Pfreundschuh M (2000).
Initiation of humoral and cellular immune responses in patients with refractory Hodgkin's disease by treatment with an anti-CD16/CD30 bispecific antibody.
Cancer Immunol. Immunother. 49 (3): 173-180
- 28) Hartmann F (2000).
Monoklonale Antikörper in der Tumorthherapie.
Med. Welt 51 (6): 172-178
- 29) Da Costa L, Renner C, Hartmann F, Pfreundschuh M (2000).
Immune recruitment by bispecific antibodies for the treatment of Hodgkin's disease.
Cancer Chemother. Pharmacol. 46 (Suppl): S33-S36
- 30) Kubuschok B, Cochlovius C, Jung W, Schmits R, Trümper L, Hartmann F, Renner C, Pfreundschuh M (2000).
Gene-modified spontaneous Epstein-Barr virus-transformed lymphoblastoid cell lines as autologous cancer vaccines: mutated p21 ras oncogene as a model.
Cancer Gene Therapy 7 (9): 1231-1240
- 31) Rick O, Bokemeyer C, Beyer J, Hartmann JT, Schwella N, Kingreen D, Neureither S, Metzner B, Casper J, Wandt H, Hartmann F, Schmoll HJ, Derigs G, Gerl A, Berdel W, Kanz L, Siegert W (2001).
Salvage treatment with paclitaxel, ifosfamide and cisplatin (TIP) plus high-dose carboplatin, etoposide and thiotepa (CET) followed by autologous stem cell rescue in patients with relapsed or refractory germ cell cancer.
J. Clin. Oncol. 19 (1): 81-88
- 32) Hartmann F, Jacobs G, Gotto H, Schwamborn J, Pfreundschuh M (2001).
Cytosine arabinoside, idarubicin and divided dose etoposide for the treatment of acute myeloid leukemia in elderly patients.
Leuk. Lymphoma 42 (3): 347-356
- 33) Hartmann F, Renner C, da Costa L, Jung W, Tembrink S, Held G, Seg A, König J, Bauer S, Kloft M, Pfreundschuh M (2001).
Anti-CD16/CD30 bispecific antibody treatment for Hodgkin's disease - Influence of infusion schedule and costimulation with cytokines.
Clin. Cancer Res. 7 (7): 1873-1881

- 34) Schmits R, Hartmann F, Beelen D, Pfreundschuh M (2001).
Neue Standards in der Therapie aggressiver Lymphome ?
Der Onkologe 7 (9): 998-1013
- 35) Renner C, Hartmann F, Pfreundschuh M (2001).
The future of monoclonal antibody engineering.
Ann. Hematol. 80 (Suppl. III): B127-B129
- 36) Hartmann F (2002).
Im focus: Tumoren wachsen nicht im leeren Raum.
HNO 50 (1) : 6-9
- 37) Hartmann F, Schmits R, Pfreundschuh M (2002).
Neue Behandlungsstrategien bei aggressiven Non-Hodgkin-Lymphomen.
Med. Welt 53 (3): 72-77
- 38) Renner C, Hartmann F, Pfreundschuh M (2002).
Immuntherapeutische Strategien zur Behandlung solider Tumoren
Dtsch. Ärztebl. 99 (13): A 850-858
- 39) Schlenk RF, Hartmann F, Hensel M, Jung W, Weber-Nordt R, Gaber A, Moos M, Haas R, Ho AD, Trümper L, Döhner H (2002).
Less intense conditioning with fludarabine, cyclophosphamid, idarubicin and etoposide (FCIE) followed by allogeneic unselected peripheral blood stem cell transplantation in elderly patients with leukemia.
Leukemia 16: 581-586
- 40) Kubuschok B, Schmits R, Hartmann F, Cochlovius C, Breit R, König J, Pistorius G, Schilling M, Renner C, Pfreundschuh M (2002).
Use of spontaneous Epstein-Barr Virus-lymphoblastoid cell lines genetically modified to express tumor antigen as cancer vaccines: mutated p21 ras oncogene in pancreatic carcinoma as a model.
Human Gene Therapy 13: 815-827
- 41) Hartmann F, Hiddemann W, Pfreundschuh M, Rube M, Trümper L (2002).
Maligne Lymphome – Educational Deutscher Krebskongreß 2002.
Der Onkologe 8 (Suppl. 1): S21-S27
- 42) Forstpointner R, Hänel A, Repp R, Herrmann S, Metzner B, Pott C, Hartmann F, Rothmann F, Böck HP, Wandt H, Unterhalt M, Hiddemann W (2002).
Rituximab zur Remissionsinduktion bei rezidivierten und refraktären indolenten Lymphomen und Mantelzell Lymphomen. Ergebnisse einer prospektiv randomisierten Studie der deutschen Studiengruppe für niedrig maligne Lymphome (GLSG).

- 43) Hofmann WK, Seipelt G, Langenhan S, Reutzel R, Schott D, Schoeffski O, Illiger HJ, Hartmann F, Balleisen L, Franke A, Fiedler F, Huber C, Rasche H, Bergmann L, Ganser A, Pott C, Pasold R, Rudolph C, Ottmann OG, Gökbuget N, Hoelzer D (2002). Prospective randomized trial to evaluate two delayed granulocyte colony stimulating factor administration schedules after high-dose cytarabine therapy in adult patients with acute lymphoblastic leukemia. *Ann. Hematol.* 81 (10): 570-574

- 44) Hartmann F, Schmits S, Pfreundschuh M (2002). Neue Chancen für ältere Patienten mit aggressiven Lymphomen. In Deutschland zu selten genutzt ? *Dtsch. Ärztebl.* 99 (48): A 3254-3264

- 45) Hofheinz RD, Al-Batran SE, Hartmann F, Hartung G, Jäger D, Renner C, Tanswell P, Kunz U, Amelsberg A, Kuthan H, Stehle G (2003). Stromal antigen targeting by a humanised monoclonal antibody: an early phase II trial of Sibrotuzumab in patients with metastatic colorectal cancer. *Onkologie* 26 (1): 44-48

- 46) Renner C, Hartmann F, Pfreundschuh M (2003). Therapeutische Antikörper (Teil 1): Moderne Klassiker. *Im Focus Onkologie* 4/2003: 45-49

- 47) Schlenk RF, Benner A, Hartmann F, del Valle F, Weber C, Pralle H, Fischer JT, Gunzer U, Pezzutto A, Weber W, Grimminger W, Preiß J, Hensel M, Fröhling S, Döhner K, Haas R, Döhner H for the AML Study Group Ulm (AML SG Ulm) (2003). Risk-adapted postremission therapy in acute myeloid leukemia: results of the German multicenter AML HD93 treatment trial. *Leukemia* 17(8): 1521-1528

- 48) Rosen O, Müller HJ, Gökbuget N, Langer W, Peter N, Schwartz S, Hähling D, Hartmann F, Ittel TH, Mück R, Rothmann F, Arnold R, Boos J, Hoelzer D (on behalf of the GMALL-study group) (2003). Pegylated asparaginase in combination with high-dose methotrexate for consolidation in adult acute lymphoblastic leukaemia in first remission: a pilot study. *Br. J. Haematol.* 123 (5): 836-841

- 49) Hartmann F, Schmits R, Pfreundschuh M (2004). Therapie aggressiver Non-Hodgkin-Lymphome. *Onkologie heute* 05/2004: 26-31

- 50) Trümper L, Glaß B, Hartmann F, Pfreunds Schuh M (2004).
Neue Diagnostik- und Therapiestrategien bei aggressiven Lymphomen
Dtsch. Med. Wschr. 129: 2113-2117
- 51) Schlenk RF, Fröhling S, Hartmann F, Fischer JT, Glasmacher A, del Valle F, Grimminger W, Götze K, Waterhouse C, Schoch R, Pralle H, Mergenthaler HG, Hensel M, Koller E, Kirchen H, Preiss J, Salwender H, Biedermann HG, Kremers S, Griesinger F, Benner A, Addamo B, Döhner K, Haas R, Döhner H (2004).
Phase III study of all-trans retinoic acid in previously untreated patients 61 years or older with acute myeloid leukemia.
Leukemia 18: 1798-1803
- 52) Forstpointner R, Dreyling M, Repp R, Herrmann S, Hänel A, Metzner B, Pott C, Hartmann F, Rothmann F, Rohrberg R, Böck HP, Wandt H, Unterhalt M, Hiddemann W (2004).
The addition of Rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared to FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas – results of a prospective randomized study of the German Low-Grade Lymphoma Study Group.
Blood 104: 3064-3071
- 53) Pfreunds Schuh M, Schmits R, Hartmann F, for the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL) (2005).
Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young good-prognosis and elderly patients with aggressive lymphomas: results of the NHL-B1 and NHL-B2 trials of the DSHNHL.
Am. J. Onc. Review 4: 184-193
- 54) Schlenk RF, Germing U, Hartmann F, Glasmacher A, Fischer JT, del Valle F, Götze K, Pralle H, Nerl C, Salwender H, Grimminger W, Petzer A, Hensel M, Zick L, Döhner K, Fröhling S, Döhner H for the AML Study Group (AMLSG) (2005).
High-dose cytarabine and mitoxantrone in consolidation therapy for acute promyelocytic leukemia.
Leukemia 19 (6): 978-983
- 55) Kubuschok B, Breit R, Neumann F, Sester M, Schormann C, Wagner C, Sester U, Hartmann F, Schmits R, Renner C, Pfreunds Schuh M (2006).
Naturally occurring T cell response against mutated p21 ras oncoprotein in pancreatic carcinoma.
Clin. Cancer Res. 12 (4): 1365-1372
- 56) Schlenk RF, Fröhling S, Hartmann F, Fischer JT, Glasmacher A, del Valle F, Götze K, Nerl C, Schoch R, Pralle H, Mergenthaler HG, Hensel M, Koller E, Kirchen H,

- Matzdorff A, Salwender H, Biedermann HG, Kremers S, Haase D, Benner A, Döhner K, Döhner H (2006).
Intensive consolidation versus oral maintenance therapy in patients 61 years or older with acute myeloid leukemia in first remission: results of second randomization of the AML HD98-B trial.
Leukemia 20: 748-750
- 57) Forstpointner R, Unterhalt M, Dreyling M, Böck HP, Repp R, Wandt H, Pott C, Seymour JF, Metzner B, Hänel A, Lehmann T, Hartmann F, Einsele H, Hiddemann W (2006).
Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, mitoxantrone (R-FCM) in patients with relapsed and refractory follicular and mantle cell lymphomas – results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG).
Blood 108: 4003-4008
- 58) Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, Reiser M, Nickenig C, Clemens M, Peter N, Bokemeyer C, Eimermacher H, Ho A, Hoffmann M, Mertelsmann R, Truemper L, Balleisen L, Liersch R, Metzner B, Hartmann F, Glass B, Poeschel V, Schmitz N, Ruebe C, Feller AC, Loeffler M for the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL) (2008).
Six versus Eight Cycles of Bi-weekly CHOP-14 with or without Rituximab for Elderly Patients with Aggressive CD20+ B-Cell Lymphomas.
Lancet Oncology 9 (2): 105-116
- 59) Schlenk RF, Döhner K, Kneba M, Götze K, Hartmann F, del Valle F, Kirchen H, Koller E, Fischer JT, Bullinger L, Habdank M, Späth D, Groner S, Krebs B, Kayser S, Corbacioglu A, Anhalt A, Benner A, Fröhling S, Döhner H for the German-Austrian AMLSG (2009).
Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B.
Haematologica 94 (1): 54-60
- 60) Schlenk RF, Döhner K, Mack S, Stoppel M, Király K, Götze K, Hartmann F, Horst HA, Koller E, Petzer A, Grimminger W, Kobbe G, Glasmacher A, Salwender H, Kirchen H, Haase D, Kremers S, Matzdorff A, Benner A, Döhner H for the German-Austrian AML Study Group (2010).
Prospective evaluation of allogeneic hematopoietic stem cell transplantation from matched related and matched unrelated donors in younger adults with high-risk acute myeloid leukemia: Results of German-Austrian AMLSG treatment trial AMLHD98A
J. Clin. Oncol. 28 (30): 4642-4648
- 61) Zwick C, Hartmann F, Zeynalova S, Poeschel V, Nickenig C, Reiser M, Lengfelder E, Peter N, Schlimok G, Balleisen L, Schmitz N, Loeffler M, Pfreundschuh M (2011):

Randomized comparison of pegfilgrastim day 4 vs. day 2 for the prevention of chemotherapy-induced leukocytopenia
Ann. Oncol. 22 (8): 1872-1877

- 62) Pfreundschuh M, Hartmann F, Renner C (2011):
Bispezifische Antikörper zur Tumortherapie
Arzneimittelforschung / Drug Research 49 (2): 177-178
- 63) Kubuschok B, Pfreundschuh M, Breit R, Hartmann F, Sester M, Gärtner B, König J, Murawski N, Held G, Zwick C, Neumann F (2012):
Mutated Ras-transfected, EBV-transformed lymphoblastoid cell lines as a model tumor vaccine for boosting T cell responses against pancreatic cancer: a pilot trial
Human Gene Therapy 23 (12): 1224-1236
- 64) Hansen T, Hartmann F, Hiller W, Schütz M, Klapper W (2014):
Primäres Hodgkin-Lymphom des Kolons. Ein Fallbericht.
Der Pathologe 2014/2: 191-195
- 65) Metzeler KH, Herold T, Rothenberg-Thurley M, Amler S, Sauerland MC, Görlich D, Schneider S, Konstandin NP, Dufour A, Bräundl K, Ksienzyk B, Zellmeier E, Hartmann L, Greif PA, Fiegl M, Subklewe M, Bohlander SK, Krug U, Faldum A, Berdel WE, Wörmann B, Büchner T, Hiddemann W, Braess J, Spiekermann K on behalf of the AMLCG study Group (Heinecke A, Sauerland MC, Görlich D, Ittel TH, Fuß H, Korsten S, Hennesser D, Mayr A, Grüneisen A, Possinger K, Blau J, Arnold R, Dörken B, Maschmeyer G, Boewer C, Derwahl M, Englisch HJ, Notter M, Thiel E, Ludwig WD, Schöndube D, Späth-Schwalbe E, Hesse S, Potenberg J, Weh AJ, Zumsprekel A, Teschendorf C, Stechstor M, Trenn G, Wörmann B, Hertenstein B, Thomssen H, Peyn A, Hallek M, Staib P, Heike M, Niederste-Hollenberg A, Pielken H, Hindahl H, Wehmeyer A, Heyll A, Aul C, Giagounidis C, Lange W, Kuhlemann SE, Flaßhove M, Karow J, Fuchs R, Schlegel F, Kiehl M, Meckenstock G, Haase D, Trümper L, Griesinger F, Gropp C, Depenbusch R, Eimermacher H, Schütte W, Haak U, Braumann D, Balleisen L, Lange JG, Schmitz-Hübner U, Fauser A, Wolf M, Ritter B, Link H, Fölsch UR, Kneba M, Dormann A, Frieling T, Planker M, Hartmann F, Middeke H, Gründgens C, Constantin C, Jost KA, Wagner T, Fetscher S, Schmielau J, Uppenkamp M, Hoffmann M, Hehlmann R, Lengfelder E, Schwonzen M, Spangenberg M, Graeven D, Kohl D, Heuer T, Emmerich B, Dengler R, Schlag B, Hiddemann W, Nibler K, Fleckenstein D, Berdel WE, Büchner T, Kienast J, Mesters R, Müller-Tidow C, Serve H, Krug U, Hartlapp J, Hegge T, Peceny R, Koch O, Innig G, Südhoff T, Kreuser ED, Schenk M, Reichle A, Andreesen R, Huff H, Schönberger D, Gassmann W, Gaske T, Frickhofen N, Fuhr, Augener W, Brugger W, Papakonstantinou G, Kreibich U, Schott G, Sommer S, Zschille W, Braess J, Amler S, de Witt M, Kallinich B, Oldenkott B, Ratei R, Behringer D, Ko YD, Zinngrebe EB, Kreuzer KA, Massenkeil G, Lindemann HW, Maciejewski CM, Roemer E, Nowak H, Biersack H, Schleyer E, Spiekermann K, Braess H, Schiel X, Hentrich M, Peceny R, Gaska T, Braees J, Schwerdtfeger R) (2016):
Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia.

- 66) Hoehstetter M, Busch R, Eichhorst B, Bühler A, Winkler D, Eckart M, Vehling-Kaiser U, Schimke H, Jäger U, Hurtz HJ, Hopfinger G, Hartmann F, Fuss H, Abenhardt W, Blau I, Freier W, Müller L, Goebeler M, Wendtner CM, Bahlo J, Fischer K, Bentz M, Emmerich B, Döhner H, Hallek M, Stilgenbauer S (2017): Early, Risk-Adapted Treatment with Fludarabine in Binet Stage A Chronic Lymphocytic Leukemia Patients: Results of the CLL1 Trial of the German CLL Study Group.
Leukemia 31 (12): 2833-2837
- 67) Hansen T, Constantin C, Weber M, Titze U, Hartmann F (2019): Bronchoalveoläre Lavage (BAL) bei Haarzell-Leukämie mit Lungeninfiltration. Ein Fallbericht.
Der Pathologe 40: 529-533
- 68) Pöschel P, Held G, Ziepert M, Witzens-Harig M, Holte H, Thurner L, Borchmann P, Viardot A, Sökler M, Keller U, Schmidt C, Trümper L, Mahlberg R, Marks R, Höffkes HG, Metzner B, Dierlamm J, Frickhofen N, Hänel M, Hoffmann J, Kneba M, Merli F, Tucci A, de Nully Brown P, Federico M, Lengfelder E, di Rocco A, Trappe R, Rosenwald A, Berdel C, Maisenhölder M, Shpilberg O, Aman J, Christophyllakis K, Hartmann F, Murawski N, Stilgenbauer S, Schmitz N, Altmann B, Löffler M, Pfreundschuh M, for the FLYER Trial Investigators (2019): Abbreviation of chemotherapy in patients with diffuse large B-cell Lymphoma with favorable prognosis
Lancet 394: 2271-2281
- 69) Hoehstetter M, Busch R, Eichhorst B, Bühler A, Winkler D, Bahlo J, Robrecht S, Eckart MJ, Vehling-Kaiser U, Schimke H, Jäger U, Hurtz HJ, Hopfinger G, Hartmann F, Fuss H, Abenhardt W, Blau I, Freier W, Müller L, Goebeler M, Wendtner C, Fischer K, Herling CD, Starck M, Bentz M, Emmerich B, Döhner H, Stilgenbauer S, Hallek M (2020): Clinical, biological and genetic parameters prospectively select early stage CLL patients for risk-adapted management: results of the CLL1 trial of the German CLL Study Group.
Leukemia 34: 1038-1051
- 70) Kiani A, Rösch R, Wendtner C, Kullmann F, Kubin T, Südhoff T, Augustin M, Schaich M, Müller-Naendrup C, Illerhaus G, Hartmann F, Hebart H, Seggewiss-Bernhardt R, Bentz M, Späth-Schwalbe E, Reimer P, Kaiser U, Kapp M, Graeven U, Chemnitz JM, Baesecke J, Lambert H, Naumann R (2021): Pre-infection laboratory parameters may predict COVID-19 severity in tumor patients: Results of the ADHOK (Arbeitsgemeinschaft Deutscher Hämatologen und Onkologen im Krankenhaus) Coronavirus Tumor Registry
Cancer Medicine 10 (13): 4424-4436

- 71) Noepel-Duenebacke S, Jütte H, Denz R, Feder IS, Kraeft AL, Lugnier C, Teschendorf C, Collette D, Böhner H, Engel L, Mueller L, Hartmann F, Kaiser U, Bruch HR, Hollerbach S, Arnold D, Timmesfeld N, Tannapfel A, Tischoff I, Reinacher-Schick A (2022).
Causes of mortality in elderly UICC stage III colon cancer (CC) patients – tumor related death and competing risks from the German AIO colorectal study group Colopredict Plus (CPP) registry.
Cancer Medicine 11 (8): 1735-1744
- 72) Al Mawed M, Brockmeier J, Haertel D, Ellermeier M, Hartmann F, Gielen S (2022).
From inoperable to back to life: a case report of successfully treated obstructive right ventricular primary cardiac lymphoma.
Eur Heart J 6 (2): 1-7
- 73) Brulke F, Zettl F, Ziepert M, Viardot A, Kahl C, Prange-Krex G, Korfel A, Dreyling M, Bott A, Wedding U, Reichert D, de Wit M, Hartmann F, Poeschel V, Schmitz N, Witzens-Harig M, Klapper W, Rosenwald A, Wulf G, Altmann B, Trümper L (2022).
First-line treatment with Rituximab and Bendamustine for old and frail patients with aggressive lymphoma: Results of the B-R-ENDA trial.
HemaSphere 6: 12(e808)